Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

Waizel, Maria; Todorova, Margarita G.; Masyk, Michael; Wolf, Katharina; Rickmann, Annekatrin; Helaiwa, Khaled; Blanke, Bjoern R.; Szurman, Peter

dc.contributor.author	Helaiwa, Khaled
dc.contributor.author	Szurman, Peter
dc.contributor.author	Blanke, Björn Rudolf
dc.date.accessioned	2017-12-18T14:42:57Z
dc.date.available	2017-12-18T14:42:57Z
dc.date.issued	2017
dc.identifier.issn	1471-2415
dc.identifier.uri	http://hdl.handle.net/10900/79432
dc.language.iso	en	de_DE
dc.publisher	Biomed Central Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1186/s12886-017-0471-x	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD	de_DE
dc.type	Article	de_DE
utue.quellen.id	20170815222223_00736
utue.personen.roh	Waizel, Maria
utue.personen.roh	Todorova, Margarita G.
utue.personen.roh	Masyk, Michael
utue.personen.roh	Wolf, Katharina
utue.personen.roh	Rickmann, Annekatrin
utue.personen.roh	Helaiwa, Khaled
utue.personen.roh	Blanke, Bjoern R.
utue.personen.roh	Szurman, Peter
dcterms.isPartOf.ZSTitelID	Bmc Ophthalmology	de_DE
dcterms.isPartOf.ZS-Issue	Article 79	de_DE
dcterms.isPartOf.ZS-Volume	17	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE